Every intervention Outliyr has scored for longevity, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for longevity; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
82 of 140 evaluated interventions score 3.0+ out of 10 for longevity · 28 comparisons
Zone 2 Cardio's 8.0/10 longevity score starts with Lang 2024, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: this verified source followed 55,137 adults and…
Read the Zone 2 Cardio report →Glycine longevity earns 8.0/10 because Kumar 2023 anchors the most relevant signal. Glycine fits longevity because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The…
Read the Glycine report →For longevity, traditional sauna scores 8.0/10 on the back of a 40 percent lower all-cause mortality association at 4 to 7 sessions per week (hazard ratio 0.60, 95% CI 0.46 to 0.80)…
Read the Traditional Sauna (Finnish Dry-Heat) report →Rapamycin longevity earns 8.0/10 because Harrison 2009 anchors the most relevant signal. Rapamycin fits longevity when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score stays bounded…
Read the Rapamycin report →The strongest longevity argument for Taurine is 7.8/10 because Singh 2023 reports Flagship aging paper; taurine declines with age and supplementation improved lifespan or healthspan markers in non-human models. The score stays…
Read the Taurine report →For longevity, Infrared Sauna lands at 7.8/10 because Kihara 2002 supports the strongest part of the claim. The existing rationale points to this narrower claim: Longevity signal comes mainly from traditional Finnish…
Read the Infrared Sauna report →Longevity is an indirect but credible Norwegian 4x4 use case, earning 7.5/10 because the protocol raises VO2max, a major marker of cardiorespiratory reserve. The original study reported about a 7% VO2max improvement…
Read the Norwegian 4×4 report →The practical longevity read on Spermidine is 7.5/10 because Kiechl 2018 anchors the strongest signal. The existing rationale points to this narrower claim: this verified source is the strongest human signal, with…
Read the Spermidine report →Longevity scores 7.0/10 because Red Light Therapy targets mitochondrial and inflammatory biology, with Hamblin 2017 supporting anti-inflammatory mechanisms. The case is healthspan-adjacent rather than lifespan-proven. No human trial shows Red Light Therapy…
Read the Red Light Therapy report →Vitamin D3 + K2 longevity earns 7.0/10 because Jolliffe 2021 anchors the most relevant signal. Vitamin D3 + K2 fits longevity when deficiency, bone risk, immune seasonality, or fat-soluble nutrient gaps are…
Read the Vitamin D3 + K2 report →Ca-AKG (Calcium Alpha-Ketoglutarate)'s 7.0/10 longevity score starts with Shahmirzadi 2020, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: this verified source reported lifespan extension in…
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Semaglutide earns 7.0/10 for longevity because Lincoff 2023 and Perkovic 2024 moved event risks that can affect lifespan in high-risk groups. The longevity case is therefore conditional, not universal. If obesity, diabetes,…
Read the Semaglutide report →Longevity earns 6.8/10 on the strength of large mortality cohorts. Grosso 2017 pooled 22 prospective studies and found high total-flavonoid intake associated with 26 percent lower all-cause mortality (RR 0.74), with flavonols…
Read the Polyphenols (Dietary) report →Senolytics scores 6.8/10 for longevity, with the best signal coming from Shimizu et al. 2025. Yousefzadeh 2018 supports fisetin lifespan and healthspan effects in mice; Farr 2024 tempers human extrapolation for D+Q.…
Read the Senolytics report →Neurofeedback is a 6.5/10 option for longevity, especially where the context resembles Sitaram et al. 2017. Longevity relevance is indirect: maintaining attention, sleep, emotional regulation, and cognitive flexibility protects functional aging. Neurofeedback…
Read the Neurofeedback report →For users targeting longevity, Molecular Hydrogen earns 6.5/10 because Dhillon 2024 reports 25-article systematic review; mixed preliminary clinical evidence, heterogeneity, and need for stronger trials. Zhou 2024 points in the same direction,…
Read the Molecular Hydrogen report →A 6.5/10 longevity rating fits GHK-Cu, since Li et al. 2015 points to a real but bounded effect. The v0 longevity score is preserved but explicitly bounded: Pickart 2014 and Pickart 2018…
Read the GHK-Cu report →Longevity scores 6.5 by inheritance from its base movement rather than from rucking trials. Walking volume is one of the most robustly mortality-linked behaviors measured: across 47,471 adults the most active step…
Read the Rucking (Weighted Walking) report →The evidence base for Whole-Body Vibration and longevity scores 6.5/10, with no direct lifespan trials but functional-aging data from older-adult reviews such as Lam et al. 2012. Whole-Body Vibration may influence longevity…
Read the Whole-Body Vibration report →Longevity is an indirect but credible use case at 6.5/10. The mechanism is VO2max, a major marker of cardiorespiratory reserve that tracks tightly with survival in Mandsager 2018, where elite fitness was…
Read the Sprinting (Sprint Interval Training) report →The longevity case for Epitalon lands at 6.5/10 because the evidence points to a plausible use case without proving a universal response. Al-dulaimi et al. 2025 is the best anchor here because…
Read the Epitalon report →Evidence from the SURMOUNT-1 extension shows tirzepatide reduced progression to type 2 diabetes, a key longevity factor (Jastreboff 2025). Tirzepatide also improves cardiometabolic risk markers such as weight, blood pressure, and lipid…
Read the Tirzepatide report →Population fit explains the 6.3/10 longevity score for Time-Restricted Eating because the evidence points to a plausible use case without proving a universal response. Chen X et al. 2026 is the best…
Read the Time-Restricted Eating report →Metformin receives a longevity use-case score of 6.2 / 10, reflecting the observational signal reported in Bannister 2014. The rationale for Metformin and longevity rests on a few epidemiologic studies that note…
Read the Metformin report →Vagus Nerve Stimulation gets 6.0/10 for longevity, with Kim et al. 2022 giving the cleanest evidence anchor. HRV is an observational mortality marker, but changing HRV with tVNS has not been shown…
Read the Vagus Nerve Stimulation report →The longevity score is 6.0/10, and TB-500 (Thymosin Beta-4 Fragment) needs careful framing. Longevity is speculative. Tissue repair, inflammation resolution, and injury resilience plausibly support healthspan, but no lifespan or age-related disease…
Read the TB-500 (Thymosin Beta-4 Fragment) report →Thymosin Alpha-1 longevity earns 6.0/10 because Wu 2025 anchors the most relevant signal. Thymosin Alpha-1 fits longevity when immune modulation is medically relevant and monitored rather than casually guessed. The score stays…
Read the Thymosin Alpha-1 report →Longevity earns 6.0/10 on one unusually strong signal. In Alehagen 2013 (KiSel-10), 200 mg CoQ10 plus 200 micrograms selenium daily in elderly Swedes cut cardiovascular mortality from 12.6% to 5.9% over roughly…
Read the Coenzyme Q10 (CoQ10 / Ubiquinol) report →Longevity lands at 6.0/10 on the strength of the framing and the cohort data, not on lifespan trials, which do not exist in humans. Beelman 2020 argues ergothioneine is a longevity vitamin…
Read the Ergothioneine report →The longevity case for Methylene Blue is 6.0/10 because Rothenberg 2025 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Longevity rationale is mitochondrial and preclinical, with…
Read the Methylene Blue report →Longevity is a 5.8/10 use case for PEMF (Pulsed Electromagnetic Field Therapy), not a blanket claim. Longevity claims are indirect and should stay modest. Lower pain, better mobility, and improved recovery can…
Read the PEMF (Pulsed Electromagnetic Field Therapy) report →Longevity scores 5.8/10 because GlyNAC is one of the few supplements with human data on multiple hallmarks of aging, not just a surrogate marker. Kumar 2023 reported improvement in several aging hallmarks…
Read the GlyNAC (Glycine + N-Acetylcysteine) report →NMN longevity earns 5.5/10 because Zhang 2024 anchors the most relevant signal. NMN fits longevity when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays…
Read the NMN (Nicotinamide Mononucleotide) report →High-Dose Melatonin has a longevity story but not a longevity trial base. The mechanisms overlap with oxidative stress, mitochondrial function, immune aging, and cellular maintenance, yet no verified human study shows lifespan…
Read the High-Dose Melatonin report →HRV Biofeedback belongs at 5.0/10 for longevity, with Goessl, Curtiss, Hofmann 2017 supporting the practical upside. Higher HRV is a solid longevity biomarker; HRV-BF directly improves this marker. Mechanism strong, direct mortality…
Read the HRV Biofeedback report →For users targeting longevity, Astaxanthin earns 5.0/10 because Liu 2024 reports 11 RCTs; 346 healthy participants; significant improvements reported across fatigue, cognition, and exercise-efficiency endpoints overall; endpoint details are limited. Maleki-Hajiagha 2024…
Read the Astaxanthin report →Urolithin A gets 5.0/10 for longevity; the evidence supports a narrow read. Ryu 2016 found lifespan extension in C. elegans and improved muscle function in rodents. Human lifespan evidence does not exist.…
Read the Urolithin A report →Longevity scores 5.0 out of 10, driven more by association than by intervention data. Brown seaweed is a documented staple of the traditional Okinawan diet, one of the world's longest-lived populations, as…
Read the Fucoidan (Brown Seaweed Polysaccharide) report →On longevity, NR (Nicotinamide Riboside) deserves 5.0/10 because Dollerup 2018 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: NAD+ decline is an established aging biology theme,…
Read the NR (Nicotinamide Riboside) report →Mechanistically, SS-31 (Elamipretide) scores 5.0/10 for longevity because the evidence points to a plausible use case without proving a universal response. Ehlers JP et al. 2024 is the best anchor here because…
Read the SS-31 (Elamipretide) report →Hachmo 2020 should be treated as hypothesis-generating because of methodological critique and financial conflicts. No authority body endorses HBOT as an anti-aging intervention.
Read the Hyperbaric Oxygen Therapy report →Chronic mTORC1 activation remains the main longevity tension. The Vangipurapu 2019 Finnish cohort linked several amino acids with worse glucose and insulin-secretion patterns, though this is observational and not an EAA supplement…
Read the Essential Amino Acids report →Vitamin C scores 4.5/10 for longevity. Adequate intake is clearly necessary for health, and severe deficiency is fatal, but the leap from adequacy to extended lifespan is not supported by human outcome…
Read the Vitamin C (Ascorbic Acid) report →Longevity claims remain capped by missing hard-outcome trials. Mechanisms such as lower insulin, mTOR suppression, AMPK activation, and BHB signaling are interesting, but human lifespan or MACE RCTs do not exist. Iatan…
Read the Ketogenic Diet report →Longevity scores 4.5/10. Glutathione decline tracks aging, and the GlyNAC work from the Sekhar group reported reversal of several aging hallmarks in older adults, but that is glycine plus N-acetylcysteine and comes…
Read the Glutathione (GSH) report →TRT has no proven longevity benefit. TestES 2024 found short-to-medium-term safety reassurance but mortality evidence remained sparse, so TRT should not be sold as a lifespan intervention.
Read the TRT (Testosterone Replacement Therapy) report →Exercise mimetics are theoretically longevity-relevant, but SLU-PP-332 has no lifespan data. Any longevity framing should be limited to pathway-level inference from ERR energy-homeostasis biology described by Giguere 2008.
Read the SLU-PP-332 report →Human longevity evidence rests on senolytic class pilots. Hickson 2019 reduced senescence markers in 11 days. Justice 2019 showed feasibility and physical function improvement in IPF. The bone trial Farr 2024 was…
Read the Quercetin report →BFR supports longevity-adjacent muscle-preservation pathways, but no direct lifespan or hard healthspan trials exist.
Read the Blood-Flow Restriction Training report →Longevity interest comes mostly from the glycine-plus-NAC (GlyNAC) glutathione-restoration work in older adults; standalone NAC has no human lifespan data. See /reports/glynac/ for the combination.
Read the NAC (N-Acetylcysteine) report →Traditional Rasayana use, antioxidant effects, bone preservation, and hormone support fit a healthspan story. No human lifespan or hard aging-outcome data exist.
Read the Shilajit report →Indirect only. Cardiometabolic risk-factor improvement is consistent with healthier aging, but there are no human lifespan or hard-outcome trials for spirulina.
Read the Spirulina report →Longevity remains indirect. Rasayana use in Ayurveda, stress reduction, sleep support, and inflammatory modulation all point in a healthspan-friendly direction, but there are no human lifespan trials. The practical longevity case is…
Read the Ashwagandha report →Longevity claims are not proven. Cochrane 2020 found little or no effect on all-cause mortality despite large trial volume.
Read the Omega-3 report →Fuku 2015 associated a MOTS-c polymorphism with exceptional longevity in Japanese centenarians, and endogenous levels relate to aging biology. No lifespan-extension study from exogenous MOTS-c exists.
Read the MOTS-c report →Longevity scoring remains cautious because GH/IGF-1 biology cuts both ways: metabolic improvements may help high-VAT adults, while higher IGF-1 can raise theoretical cancer-growth concern in susceptible users.
Read the Tesamorelin report →Longevity is the most eye-catching claim and the weakest-supported. The flagship 266-person elderly cohort reported mortality falling roughly 2 to 4 fold over 6 years, per Khavinson 2003. That is an extraordinary…
Read the Thymalin report →Longevity scores 4.0 out of 10, driven by a single suggestive animal model and traditional framing. Mao 2012 reported that pine pollen improved memory, lowered inflammatory cytokines, and delayed fibroblast senescence in…
Read the Pine Pollen report →No longevity or lifespan data exists for Tβ4 in any species. The peptide is studied as a tissue-repair agent, not a longevity intervention; the antifibrotic Ac-SDKP arm is mechanistically interesting for aging…
Read the Thymosin Beta-4 (Tβ4) report →Longevity evidence is mechanistic and indirect through mood, sleep, metabolic markers, and retinal preservation; saffron has no human lifespan, mortality, or aging-clock endpoint.
Read the Saffron report →Glycine and connective-tissue maintenance fit healthspan logic, but collagen peptides have no human lifespan or mortality trials. Longevity claims should stay conservative.
Read the Collagen Peptides report →Tissue repair and cytoprotection; no lifespan studies. Maintenance use for longevity is community practice without trial support.
Read the BPC-157 report →Muscle preservation tracks with longevity, but WB-EMS has no lifespan or mortality trials. This is a muscle-maintenance proxy score, strongest when EMS helps someone train who otherwise would not.
Read the Full-Body EMS report →Neuroprotection is longevity-adjacent, but Semax has no lifespan, all-cause mortality, dementia-prevention, or long-term healthspan trial.
Read the Semax report →The nutrient density and modest cardiometabolic effects are longevity-adjacent, but there is no human lifespan or healthspan outcome evidence for chlorella, so this is mechanistic optimism, not data.
Read the Chlorella report →The longevity use case is the original resveratrol story and the weakest clinical reason to supplement. Pacholec 2010 found resveratrol was not a direct SIRT1 activator under native-substrate assays, and Mansouri 2025…
Read the Resveratrol report →No human longevity trial has tested C15:0 supplementation against mortality, frailty, biological-age clocks, telomeres, or healthspan endpoints. Ciesielski 2024 (Ciesielski 2024) frames essentiality as controversial rather than settled. The longevity pitch is…
Read the C15 (Pentadecanoic Acid) report →C60 longevity remains weak because Baati 2012 is small animal evidence and Shytikov 2021 found C60 similar to water controls, not a clean lifespan extension. The 2024 to 2026 audit found no…
Read the C60 (Buckminsterfullerene) report →AMPK, mTOR, glucose, inflammation, and microbiome mechanisms are longevity-adjacent, but there is no human lifespan data. Berberine is better seen as metabolic risk management in selected users than a broad longevity supplement.
Read the Berberine report →No human longevity data. Mechanistic and animal signals only. The marketing outruns the evidence here.
Read the Curcumin report →Chronic dehydration and extreme sodium patterns track with risk, but ordinary supplementation is preventive support rather than a longevity intervention.
Read the Electrolytes report →Membrane integrity and cortisol regulation are aging-relevant, but no lifespan, mortality, or long-term disease-prevention RCTs support PS as a longevity intervention.
Read the Phosphatidylserine report →Longevity support is indirect through neuroprotection, gut, immune, and inflammation pathways. No lifespan RCT, human cohort, or validated aging-biomarker trial supports a high score.
Read the Lion’s Mane report →No longevity endpoint data exist. The mechanism is functional and short-lived, not a durable aging-pathway intervention.
Read the Tongkat Ali report →CD38 inhibition is the primary longevity claim. Escande 2013 showed apigenin inhibited CD38 and increased NAD+ in cells and mice. No human trial confirms NAD+ elevation, healthspan benefit, or longevity-relevant outcomes at…
Read the Apigenin report →Animal lifespan data on ketogenic states exist, but there is no human longevity evidence for exogenous ketones, and the acute-only pharmacology makes a durable aging effect unlikely from intermittent dosing.
Read the Exogenous Ketones report →No human longevity or healthspan endpoint has been tested. The pitch rests on historical mystique, not outcome data.
Read the Quinton Marine Plasma (Seawater Minerals) report →Traditional longevity tonics with antioxidant and immune mechanisms, but no human lifespan or healthspan outcome data. Mechanism-only.
Read the Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) report →Retatrutide has no lifespan or long-term disease-outcome evidence. Treating it as a longevity intervention in healthy adults overreaches the data and ignores the FDA and authority gaps documented in the audit.
Read the Retatrutide report →Chronic IGF-1 elevation has epidemiological cancer-risk associations, including Endogenous Hormones Collaborative Group 2010. Longevity trade-off is negative to neutral.
Read the CJC-1295 report →Longevity is humanin's most interesting and most cited use case, yet it stays modest because the human evidence is correlational, not interventional. Children of centenarians carry much higher circulating humanin, the peptide…
Read the Humanin report →Longevity is the central pitch because NAD+ declines with age, per Massudi 2012, and restoring it is a major aging hypothesis, per Rajman 2018. But no human longevity or healthspan trial exists…
Read the NAD+ (Direct) report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Tirzepatide, at 6.1, then semaglutide at 6.0, then orforglipron at 5.8 if you want the pill. All three are approved, all three have real trial evidence, and all…
Ca-AKG, urolithin A and MOTS-c tie at 6.5, and only the first two are things you can legally buy. SS-31 follows at 6.0. The bottom three score low…
GHK-Cu wins this on evidence. It has human wound and skin data behind it. AHK-Cu has one unreplicated dish study and no human trial at all. Use GHK-Cu…
Neither, if fat loss is the goal. Both score 2.0 on body composition, which is the row a vendor sells them on. AOD-9604 scores 4.6 overall and its…
Melatonin, dosed low. It scores 8.2 against apigenin's 6.7 and wins the sleep rows outright. The morning hangover apigenin markets against comes from taking too much, not from…
BPC-157 for structural repair, KPV for inflammation you cannot afford to stimulate. BPC-157 scores gut health 9.0 against KPV's 7.0 and wins nearly every other row, because it…
Bromantane, for anything you plan to repeat. It scores 7.1 against phenylpiracetam's 5.5 and wins every shared use case that is not a floor tie: energy 6.2 to…
Cerebrolysin scores 6.3 and P-21 scores 5.0, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
CoQ10 scores 7.1 and methylene blue 6.1, yet methylene blue wins eleven of the seventeen shared use cases. The overall gap is risk, not effect. Methylene blue inhibits…
Neither, yet. Both have zero human trials, zero human pharmacokinetics and research-only access. PE-22-28 scores 4.9 and dihexa 4.4, and the gap is entirely safety: dihexa potentiates the…
Epitalon, if sleep is the question. It scores sleep quality 6.5 against pinealon's 1.7, because it acts on the pineal gland and melatonin output while pinealon is a…
The scores tie at 6.3 and 6.4 and every shared subrating sits within half a point, so the numbers decide nothing. Access and evidence decide it. Gonadorelin is…
Zone 2 Cardio, at 8.0 out of 10 for longevity. Zone 2 Cardio's 8.0/10 longevity score starts with Lang 2024, then gets narrowed by the evidence gap.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 8.0 out of 10 for longevity.
82 of the 140 interventions evaluated for longevity score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
